SAfety of Regional Citrate Anticoagulation (SARCA Study)
An Open-label, Prospective, Multicenter Study to Assess the SAfety of Regional Citrate Anticoagulation Delivered by the multiFiltratePRO System in Adult Patients Requiring Continuous Renal Replacement Therapy (SARCA Study)
Fresenius Medical Care North America
50 participants
Oct 17, 2023
INTERVENTIONAL
Conditions
Summary
This is an Open-label, Prospective, Multicenter Study to Assess the SAfety of Regional Citrate Anticoagulation Delivered by the multiFiltratePRO system in Adult Patients Requiring Continuous Renal Replacement Therapy (SARCA Study).
Eligibility
Inclusion Criteria6
- Signed informed consent form by
- The subject or
- A legally authorized representative (LAR), if the subject is unable to consent
- Adult patients ≥ 18 years old
- Diagnosis of AKI or End-Stage Kidney Disease (ESKD) requiring CRRT
- Vascular access - Dialysis Catheter with size and location per institutional practice
Exclusion Criteria7
- Metabolic alkalosis as defined by serum bicarbonate greater than 30 mmol/L and arterial pH greater than 7.55
- A female who is pregnant or breast feeding
- Severe liver disease defined as International Normalized Ratio (INR) greater than 2.0 and total bilirubin greater than 5 mg/dl, and both aspartate aminotransferase (AST) and alanine aminotransferase (ALT) greater than 3 times upper limit of normal
- Subjects currently enrolled in or who have completed any other investigational drug or device study within last 30 days prior to signing informed consent
- Previous participation in a similar or the same study.
- Subjects already on continuous renal replacement therapy
- Subjects with active COVID-19 infection
Interventions
In this study critically ill adult patients requiring Continuous Renal Replacement Therapy (CRRT) will receive Regional Citrate Anticoagulation (CRA) which will be delivered by multiFiltratePRO system.
Locations(10)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05339139